The Role of miRNA in the Pathophysiology of Neuroendocrine Tumors

• Main Authors: Lukas Geisler, Raphael Mohr, Joeri Lambrecht, Jana Knorr, Henning Jann, Sven H. Loosen, Burcin Özdirik, Tom Luedde, Linda Hammerich, Frank Tacke, Alexander Wree, Teresa Hellberg, Christoph Roderburg
• Format: Article
• Language: English
• Published: MDPI AG 2021-08-01
• Series: International Journal of Molecular Sciences
• Subjects: NET; miRNA; biomarker; prognosis; diagnosis
• Online Access: https://www.mdpi.com/1422-0067/22/16/8569

Neuroendocrine tumors (NETs) represent a tumor group that is both rare and heterogeneous. Prognosis is largely determined by the tumor grading and the site of the primary tumor and metastases. Despite intensive research efforts, only modest advances in diagnostic and therapeutic approaches have been achieved in recent years. For patients with non-respectable tumor stages, prognosis is poor. In this context, the development of novel diagnostic tools for early detection of NETs and prediction of tumor response to therapy as well as estimation of the overall prognosis would greatly improve the clinical management of NETs. However, identification of novel diagnostic molecules is hampered by an inadequate understanding of the pathophysiology of neuroendocrine malignancies. It has recently been demonstrated that microRNA (miRNA), a family of small RNA molecules with an established role in the pathophysiology of quite different cancer entities, may also play a role as a biomarker. Here, we summarize the available knowledge on the role of miRNAs in the development of NET and highlight their potential use as serum-based biomarkers in the context of this disease. We discuss important challenges currently preventing their use in clinical routine and give an outlook on future directions of miRNA research in NET.